The FDA has approved marijuana for AIDS and cancer patients. The United States Food and Drug Administration (FDA), recently approved a liquid variety of synthetic tetrahydrocannabinol that will be sold to people suffering from AIDS and Cancer. It was revealed earlier this month that a company called Insys Therapeutics is gearing up to dive into the marijuana market, worth hundreds of millions, with their new FDA, approved a version of dronabinol.
The first of its kind liquid THC synthetic will be sold on pharmacy shelves under “Syndros” and will help treat “anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.”Although dronabinol is nothing new, it is rarely turned into a liquid for consumption. This easy to swallow method has a quicker absorption rate than its pill counterpart and is, therefore, better
Although dronabinol is nothing new, it is rarely turned into a liquid for consumption. This easy to swallow method has a quicker absorption rate than its pill counterpart and is, therefore, better in the long run. A press release by Insys says that the drug company plans on converting a majority of their dronabinol business to Syndros, by meeting with over 8,000 physicians to teach them about the benefits of the product.
“When the drug became available in the mid-1980s, scientists thought it would have the same effect as the whole cannabis plant. But it soon became clear that most patients preferred using the whole plant to taking Marinol,” said Dr. Sanjay Gupta, on CNN back in 2014. “Researchers began to realize that other components, such as CBD, might have a larger role than previously realized.”
But some drug companies such as Insys and GW Pharmaceuticals are on track to bring a CBD based epilepsy drug called Epidolex to pharmacy everywhere and are speaking to the government about calling it a “safe and effective” drug within the marketplace. By dissecting the cannabis plants, drug controllers are able to keep a tight watch over the product, preventing it from getting into the wrong hands. Insys Therapeutics forecasts a $700 million annual revenue from the sale of Syndros